
Promising pancreatic cancer drug triggers patient surge ahead of FDA decision
A promising pancreatic cancer therapy, daraxonrasib from Revolution Medicines, has sparked a rapid wave of patient inquiries and clinic access discussions in the US as doctors rush to coordinate expedited FDA review and company-led enrollment; early trial data show a substantial survival improvement compared with standard chemotherapy, but the treatment is not a cure and access involves a multi-step process.













